Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 20/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30677217 | 1.00 | PTPN11 (0.71) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL23063939 | 0.91 | PTPN11 (0.71) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL30677174 | 0.88 | PTPN11 (0.58) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL23100852 | 0.88 | PTPN11 (0.58) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL23100844 | 0.88 | PTPN11 (0.69) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL30809748 | 0.88 | PTPN11 (0.69) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL23126447 | 0.87 | PTPN11 (0.72) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL23063963 | 0.87 | PTPN11 (0.71) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL23064013 | 0.86 | PTPN11 (0.72) | PTPN11 | |
| SCHEMBL30677173 | 0.86 | PTPN11 (0.72) | PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932643-B2 | Substituted heterocyclic inhibitors of PTPN11 | NAVIRE PHARMA, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| CN-112351780-B | Substituted heterocyclic inhibitors of PTPN11 | 纳维尔制药有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20210317122-A1 | SUBSTITUTED HETEROCYCLIC INHIBITORS OF PTPN11 | Cantero Therapeutics, Inc. | 2021-10-14 | — | — | US | disclosed |
| US-20210317122-A1 | SUBSTITUTED HETEROCYCLIC INHIBITORS OF PTPN11 | Cantero Therapeutics, Inc. | 2021-10-14 | — | — | US | disclosed |
| US-10954243-B2 | Substituted heterocyclic inhibitors of PTPN11 | NAVIRE PHARMA, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-10954243-B2 | Substituted heterocyclic inhibitors of PTPN11 | NAVIRE PHARMA, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3787627-A1 | SUBSTITUTED HETEROCYCLIC INHIBITORS OF PTPN11 | Navire Pharma, Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| CN-112351780-A | Substituted heterocyclic inhibitors of PTPN11 | 纳维尔制药有限公司 | 2021-02-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10954243-B2 | Substituted heterocyclic inhibitors of PTPN11 | PTPN11, PTPRJ, PTPRCAP | PTPN11 1/4885KCNH2 4200/4885MAPK3 204/4885 |
| US-11932643-B2 | Substituted heterocyclic inhibitors of PTPN11 | PTPN11, PTPRJ, PTPRCAP | PTPN11 1/4885KCNH2 4200/4885MAPK3 204/4885 |
| US-20210317122-A1 | SUBSTITUTED HETEROCYCLIC INHIBITORS OF PTPN11 | PTPN11, PTPRJ, PTPRCAP | PTPN11 1/4885KCNH2 4200/4885MAPK3 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.